Christina Parsinevila

In this discussion, Christina Parsinevila, a Nasdaq reporter with a keen eye on investment trends, dives into the recent dynamics of chip stocks and the Federal Reserve's potential decisions. She highlights the challenges faced by Intel amidst political influences and inflation concerns. The conversation shifts to Viking Therapeutics’ disappointing weight-loss drug trials, drawing interesting comparisons to competitors like Eli Lilly and Novo Nordisk. Parsinevila also explores the current landscape of mega-cap tech stocks and undervalued opportunities in the market.